Side-by-side · Research reference

GlutathionevsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED6/39 cited

BPhase 2HUMAN-REVIEWED8/46 cited

Glutathione

Endogenous Tripeptide · Antioxidant

γ-Glu-Cys-GlyStructure

UbiquitousTissue distribution

GCL + GSBiosynthesisWang 2026 Aiana 2026

IV · Oral · Inhaled

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

Glutathione

TB-500

Primary target

Intracellular redox systems, glutathione peroxidase, glutathione transferase

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Synthesized via glutamate-cysteine ligase (GCL) → γ-glutamylcysteine → glutathione synthetase (GS) → GSH

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Reduction of reactive oxygen species, conjugation of electrophiles, maintenance of cellular thiol-disulfide balance, GPX4 activation for lipid peroxide reduction

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

—

Endogenous protein at baseline; supplementation amplifies

Origin

Endogenous tripeptide; predominantly synthesized in liver, exported to extracellular space and tissuesTerrell 2025 Hecht 2026

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

Glutathione

TB-500

Endogenous synthesis

Hepatic synthesis ~10 g/day (basal rate)

Tissue-specific; demand-driven upregulation via Nrf2 signaling.

—

Exogenous oral

250–1000 mg/day

Bioavailability limited; gastric hydrolysis reduces systemic uptake.

—

IV supplementation

600–1200 mg (research protocols)

Used in clinical oxidative stress and hepatic detoxification studies.

—

Precursor strategy

N-acetylcysteine (NAC) 600–1200 mg/day

Provides cysteine for endogenous GSH synthesis; bypasses GI degradation.

—

Evidence basis

Animal mechanistic + human mechanistic

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Standard dose

—

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Frequency

—

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

—

1 mg per injection

Duration

—

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

—

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

—

Evening or pre-rest preferred (anecdotal)

Half-life

—

~2 hours (estimated; tissue uptake longer)

04Side Effects & Safety

Parameter

Glutathione

TB-500

Oral supplementation

GI discomfort, bloating (mild, dose-dependent)

—

IV administration

Rare hypersensitivity, infusion site reaction

—

Inhalation

Bronchospasm risk in asthma (rare)

—

Tumor metabolism

Extracellular GSH catabolism supplies cysteine to tumors; theoretical concern in active malignancyHecht 2026

—

Injection site reaction

—

Mild erythema, transient pain

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid

Long-term safety

—

Unknown beyond Phase 2

Absolute Contraindications

Glutathione

—

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

Glutathione

·Active malignancy (theoretical cysteine supply risk)Hecht 2026
·Severe asthma (inhaled formulations)

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

Glutathione

TB-500

1. Oral administration

Capsule or liquid form, 250–1000 mg once daily. Take on empty stomach for improved absorption, though GI hydrolysis limits bioavailability. NAC precursor strategy often preferred.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Intravenous

Clinical protocols: 600–1200 mg slow infusion over 30–60 minutes. Used for acute oxidative stress, hepatic detoxification support. Administered in medical settings.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Inhaled formulations

Nebulized GSH (research protocols). Monitor for bronchospasm in reactive airway patients. Used experimentally for pulmonary oxidative stress.

Evening or pre-sleep is most common anecdotal timing.

4. Precursor supplementation

N-acetylcysteine (NAC) 600–1200 mg/day PO. Provides cysteine substrate for endogenous GSH synthesis. Bypasses gastric degradation, preferred for chronic supplementation.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Needle

—

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Glutathione

— no documented stacks

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair